Victor Moussa / Shutterstock.com
The US Patent Trial and Appeal Board (PTAB) has instituted an inter partes review (IPR) into a patent covering an opioid overdose treatment owned by Nalox-1 Pharmaceuticals.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
US Patent Trial and Appeal Board, Nalox-1 Pharmaceuticals, Opiant Pharmaceuticals, naloxone, Narcan, inter partes review